Actively Recruiting
Monotherapy of an NMDA Enhancer for Schizophrenia
Led by China Medical University Hospital · Updated on 2026-03-24
80
Participants Needed
1
Research Sites
517 weeks
Total Duration
On this page
Sponsors
C
China Medical University Hospital
Lead Sponsor
N
National Health Research Institutes, Taiwan
Collaborating Sponsor
AI-Summary
What this Trial Is About
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.
CONDITIONS
Official Title
Monotherapy of an NMDA Enhancer for Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a DSM-5 diagnosis of schizophrenia
- Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects
- PANSS total score of 60 or higher
- Free of antipsychotic drugs for at least 1 week
- Agree to participate and provide informed consent
You will not qualify if you...
- Current substance abuse or substance dependence in the past 3 months
- History of epilepsy, head trauma, stroke, or other serious medical or neurological illness
- Use of depot antipsychotic in the past 3 months
- Clinically significant abnormal laboratory screening tests
- Pregnancy or breastfeeding
- Inability to follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan
Actively Recruiting
Research Team
H
Hsien-Yuan Lane, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here